New strategic insights into managing fungal biofilms

Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation, or other chronic diseases. Such opportunistic infections result from a complex relationship between...

Full description

Bibliographic Details
Main Authors:	Borghi, Elisa, Morace, Giulia, Borgo, Francesca, Rajendran, Ranjith, Sherry, Leighann, Nile, Christopher, Ramage, Gordon
Format:	Online
Language:	English
Published:	Frontiers Media S.A. 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594024/

id	pubmed-4594024
recordtype	oai_dc
spelling	pubmed-45940242015-10-23 New strategic insights into managing fungal biofilms Borghi, Elisa Morace, Giulia Borgo, Francesca Rajendran, Ranjith Sherry, Leighann Nile, Christopher Ramage, Gordon Microbiology Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation, or other chronic diseases. Such opportunistic infections result from a complex relationship between fungi and host, and can range from self-limiting to chronic or life-threatening infections. Modern medicine, characterized by a wide use of biomedical devices, offers new niches for fungi to colonize and form biofilm communities. The capability of fungi to form biofilms is well documented and associated with increased drug tolerance and resistance. In addition, biofilm formation facilitates persistence in the host promoting a persistent inflammatory condition. With a limited availability of antifungals within our arsenal, new therapeutic approaches able to address both host and pathogenic factors that promote fungal disease progression, i.e., chronic inflammation and biofilm formation, could represent an advantage in the clinical setting. In this paper we discuss the antifungal properties of myriocin, fulvic acid, and acetylcholine in light of their already known anti-inflammatory activity and as candidate dual action therapeutics to treat opportunistic fungal infections. Frontiers Media S.A. 2015-10-06 /pmc/articles/PMC4594024/ /pubmed/26500623 http://dx.doi.org/10.3389/fmicb.2015.01077 Text en Copyright © 2015 Borghi, Morace, Borgo, Rajendran, Sherry, Nile and Ramage. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Borghi, Elisa Morace, Giulia Borgo, Francesca Rajendran, Ranjith Sherry, Leighann Nile, Christopher Ramage, Gordon
spellingShingle	Borghi, Elisa Morace, Giulia Borgo, Francesca Rajendran, Ranjith Sherry, Leighann Nile, Christopher Ramage, Gordon New strategic insights into managing fungal biofilms
author_facet	Borghi, Elisa Morace, Giulia Borgo, Francesca Rajendran, Ranjith Sherry, Leighann Nile, Christopher Ramage, Gordon
author_sort	Borghi, Elisa
title	New strategic insights into managing fungal biofilms
title_short	New strategic insights into managing fungal biofilms
title_full	New strategic insights into managing fungal biofilms
title_fullStr	New strategic insights into managing fungal biofilms
title_full_unstemmed	New strategic insights into managing fungal biofilms
title_sort	new strategic insights into managing fungal biofilms
description	Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation, or other chronic diseases. Such opportunistic infections result from a complex relationship between fungi and host, and can range from self-limiting to chronic or life-threatening infections. Modern medicine, characterized by a wide use of biomedical devices, offers new niches for fungi to colonize and form biofilm communities. The capability of fungi to form biofilms is well documented and associated with increased drug tolerance and resistance. In addition, biofilm formation facilitates persistence in the host promoting a persistent inflammatory condition. With a limited availability of antifungals within our arsenal, new therapeutic approaches able to address both host and pathogenic factors that promote fungal disease progression, i.e., chronic inflammation and biofilm formation, could represent an advantage in the clinical setting. In this paper we discuss the antifungal properties of myriocin, fulvic acid, and acetylcholine in light of their already known anti-inflammatory activity and as candidate dual action therapeutics to treat opportunistic fungal infections.
publisher	Frontiers Media S.A.
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594024/
_version_	1613483712007110656

New strategic insights into managing fungal biofilms

Similar Items